Physician profile
Chris M Kramer
NPI 1245221969
$1,817.97
in general payments reported to CMS, 2019-2025
20 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $166 · 2021: $207 · 2022: $248 · 2023: $334 · 2024: $285 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $255.84 | 2022-2025 | Hydrus Microstent, Rocklatan, Voyager Dslt |
| Novartis Pharmaceuticals Corporation | $228.30 | 2019-2023 | |
| Abbvie INC. | $205.63 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $201.78 | 2019 | |
| Kala Pharmaceuticals, INC. | $169.03 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $119.85 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $117.92 | 2021-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $110.93 | 2023-2025 | Yutiq, Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $78.77 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $52.12 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $43.98 | 2019-2022 | |
| Sight Sciences, INC. | $43.96 | 2022 | |
| Aerie Pharmaceuticals, INC. | $39.98 | 2021 | |
| Biotissue Holdings INC. | $38.37 | 2024 | |
| Sun Pharmaceutical Industries INC. | $35.94 | 2022-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.68 | 2021 | |
| Dompe US, INC. | $14.70 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $14.24 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $13.36 | 2021 | |
| Shire North American Group INC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.